BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22139909)

  • 1. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.
    Khoury HJ; Garcia-Manero G; Borthakur G; Kadia T; Foudray MC; Arellano M; Langston A; Bethelmie-Bryan B; Rush S; Litwiler K; Karan S; Simmons H; Marcus AI; Ptaszynski M; Kantarjian H
    Cancer; 2012 Jul; 118(14):3556-64. PubMed ID: 22139909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.
    LoRusso PM; Goncalves PH; Casetta L; Carter JA; Litwiler K; Roseberry D; Rush S; Schreiber J; Simmons HM; Ptaszynski M; Sausville EA
    Invest New Drugs; 2015 Apr; 33(2):440-9. PubMed ID: 25684345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.
    Infante JR; Patnaik A; Verschraegen CF; Olszanski AJ; Shaheen M; Burris HA; Tolcher AW; Papadopoulos KP; Beeram M; Hynes SM; Leohr J; Lin AB; Li LQ; McGlothlin A; Farrington DL; Westin EH; Cohen RB
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):315-326. PubMed ID: 28097385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors.
    Wakui H; Yamamoto N; Kitazono S; Mizugaki H; Nakamichi S; Fujiwara Y; Nokihara H; Yamada Y; Suzuki K; Kanda H; Akinaga S; Tamura T
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):15-23. PubMed ID: 24752449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.
    Holen K; DiPaola R; Liu G; Tan AR; Wilding G; Hsu K; Agrawal N; Chen C; Xue L; Rosenberg E; Stein M
    Invest New Drugs; 2012 Jun; 30(3):1088-95. PubMed ID: 21424701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
    Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
    Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.
    Holen KD; Belani CP; Wilding G; Ramalingam S; Volkman JL; Ramanathan RK; Vasist LS; Bowen CJ; Hodge JP; Dar MM; Ho PT
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):447-54. PubMed ID: 20461380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells.
    Carter BZ; Mak DH; Woessner R; Gross S; Schober WD; Estrov Z; Kantarjian H; Andreeff M
    Leukemia; 2009 Oct; 23(10):1755-62. PubMed ID: 19458629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.
    Hollebecque A; Deutsch E; Massard C; Gomez-Roca C; Bahleda R; Ribrag V; Bourgier C; Lazar V; Lacroix L; Gazzah A; Varga A; de Baere T; Beier F; Kroesser S; Trang K; Zenke FT; Klevesath M; Soria JC
    Invest New Drugs; 2013 Dec; 31(6):1530-8. PubMed ID: 24077982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
    Cortes J; Faderl S; Estey E; Kurzrock R; Thomas D; Beran M; Garcia-Manero G; Ferrajoli A; Giles F; Koller C; O'Brien S; Wright J; Bai SA; Kantarjian H
    J Clin Oncol; 2005 Apr; 23(12):2805-12. PubMed ID: 15728224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
    Burris HA; Jones SF; Williams DD; Kathman SJ; Hodge JP; Pandite L; Ho PT; Boerner SA; Lorusso P
    Invest New Drugs; 2011 Jun; 29(3):467-72. PubMed ID: 20069338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
    Gomez HL; Philco M; Pimentel P; Kiyan M; Monsalvo ML; Conlan MG; Saikali KG; Chen MM; Seroogy JJ; Wolff AA; Escandon RD
    Anticancer Drugs; 2012 Mar; 23(3):335-41. PubMed ID: 22123335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.
    Garcia-Manero G; Khoury HJ; Jabbour E; Lancet J; Winski SL; Cable L; Rush S; Maloney L; Hogeland G; Ptaszynski M; Calvo MC; Bohannan Z; List A; Kantarjian H; Komrokji R
    Clin Cancer Res; 2015 Mar; 21(5):985-94. PubMed ID: 25480830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
    Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
    J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
    Foran J; Ravandi F; Wierda W; Garcia-Manero G; Verstovsek S; Kadia T; Burger J; Yule M; Langford G; Lyons J; Ayrton J; Lock V; Borthakur G; Cortes J; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):223-30. PubMed ID: 24355079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
    Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
    J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520.
    Tunquist BJ; Woessner RD; Walker DH
    Mol Cancer Ther; 2010 Jul; 9(7):2046-56. PubMed ID: 20571074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
    Shah JJ; Kaufman JL; Zonder JA; Cohen AD; Bensinger WI; Hilder BW; Rush SA; Walker DH; Tunquist BJ; Litwiler KS; Ptaszynski M; Orlowski RZ; Lonial S
    Cancer; 2017 Dec; 123(23):4617-4630. PubMed ID: 28817190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.
    Gojo I; Perl A; Luger S; Baer MR; Norsworthy KJ; Bauer KS; Tidwell M; Fleckinger S; Carroll M; Sausville EA
    Invest New Drugs; 2013 Oct; 31(5):1217-27. PubMed ID: 23443507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.